Wagenvoort Gertjan H J, Sanders Elisabeth A M, de Melker Hester E, van der Ende Arie, Vlaminckx Bart J, Knol Mirjam J
Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Immunology and Infectious Diseases, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Vaccine. 2017 Mar 27;35(14):1749-1757. doi: 10.1016/j.vaccine.2017.02.037. Epub 2017 Mar 3.
Short-term mortality after invasive pneumococcal disease (IPD) and pneumococcal pneumonia is high but data on long-term mortality (including the comparison between bacteremic and non-invasive/non-bacteremic pneumococcal pneumonia) within the first years after diagnosis are scarce.
Adult patients with 'non-pneumonia' IPD and 'invasive pneumonia' (from 2004 to 2012) and with 'bacteremic' vs 'non-invasive/non-bacteremic (NI/NB)' pneumococcal pneumonia (from 2008 to 2012) diagnosed by negative blood culture but a positive urinary antigen test (UAT) were identified in a Dutch hospital. Mortality of patients up to 10years after diagnosis was compared with age- and sex-matched life-expectancy data of the general population. Multivariable Cox regression analysis was used to study predictors for mortality in invasive pneumonia patients and to adjust for confounders comparing mortality between bacteremic and NI/NB/UAT-positive pneumonia patients.
Of 228 invasive pneumonia patients 17% died within 30days and in 30-day survivors cumulative long-term mortality at 1 and 5years were 16% and 39% as compared with 3% and 15% in age- and sex-matched persons. High mortality was largely dependent on pre-existent comorbidities. In invasive pneumonia patients who survived the first 30days, age, male gender, chronic cardiovascular disease, malignancy and PCV7 serotype disease were independent predictors for higher long-term mortality. For bacteremic pneumonia patients (n=128) 30-day mortality was 16% and almost similar to 14% in NI/NB/UAT-positive pneumococcal pneumonia patients (n=170). In 30-day survivors of bacteremic pneumonia (n=108, median age 66years), cumulative mortality at 1 and 3years were 13% and 29% as compared with 18% and 40% in NI/NB/UAT-positive pneumococcal pneumonia patients (n=146, median age 67years) without a significant difference in mortality.
Approximately 40% of all patients, who survived the first 30days after presentation with non-pneumonia IPD and pneumococcal pneumonia died within the following 5years. High long-term mortality was largely dependent on pre-existent comorbidity.
侵袭性肺炎球菌病(IPD)和肺炎球菌肺炎后的短期死亡率很高,但关于诊断后最初几年内长期死亡率的数据(包括菌血症性与非侵袭性/非菌血症性肺炎球菌肺炎之间的比较)却很稀少。
在一家荷兰医院中,识别出通过血培养阴性但尿抗原检测(UAT)呈阳性诊断出的“非肺炎”IPD和“侵袭性肺炎”(2004年至2012年)以及菌血症性与非侵袭性/非菌血症性(NI/NB)肺炎球菌肺炎(2008年至2012年)的成年患者。将诊断后长达10年的患者死亡率与一般人群的年龄和性别匹配的预期寿命数据进行比较。使用多变量Cox回归分析来研究侵袭性肺炎患者死亡率的预测因素,并对菌血症性与NI/NB/UAT阳性肺炎患者之间的死亡率进行混杂因素调整比较。
在228例侵袭性肺炎患者中,17%在30天内死亡,30天存活者中1年和5年的累积长期死亡率分别为16%和39%,而年龄和性别匹配者分别为3%和15%。高死亡率在很大程度上取决于预先存在的合并症。在最初30天存活的侵袭性肺炎患者中,年龄、男性、慢性心血管疾病、恶性肿瘤和PCV7血清型疾病是长期死亡率较高的独立预测因素。对于菌血症性肺炎患者(n = 128),30天死亡率为16%,与NI/NB/UAT阳性肺炎球菌肺炎患者(n = 170)的14%几乎相似。在菌血症性肺炎的30天存活者(n = 108,中位年龄66岁)中,1年和3年的累积死亡率分别为13%和29%,而NI/NB/UAT阳性肺炎球菌肺炎患者(n = 146,中位年龄67岁)分别为18%和40%,死亡率无显著差异。
在出现非肺炎IPD和肺炎球菌肺炎后最初30天存活的所有患者中,约40%在接下来的5年内死亡。高长期死亡率在很大程度上取决于预先存在的合并症。